Myotonic dystrophy: Is a narrow focus obscuring the rest of the field?

Current Opinion in Neurology

Volumn 25, Issue 5, 2012, Pages 609-613

  Mahadevan, Mani S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

MBNL1; myotonic dystrophy; RNA foci; RNA toxicity; therapeutic development

Indexed keywords

CHLORIDE CHANNEL; MYOTONIC DYSTROPHY PROTEIN KINASE; RNA;

3' UNTRANSLATED REGION; CLINICAL RESEARCH; DEFIBRILLATOR; GENE EXPRESSION; HEART CONDUCTION; HISTOPATHOLOGY; HUMAN; MUSCLE ATROPHY; MYOTONIC DYSTROPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PACEMAKER; PATHOGENESIS; REVIEW; RNA BINDING; RNA SPLICING; RNA TRANSLATION;

ANIMALS; DEFIBRILLATORS, IMPLANTABLE; HUMANS; MICE; MUTATION; MYOTONIC DYSTROPHY; RNA; RNA, ANTISENSE; RNA-BINDING PROTEINS;

EID: 84866335840     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328357b0d9     Document Type: Review

References (55)

1. Mathieu J, Allard P, Potvin L, et al. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology 1999; 52:1658-1662. (Pubitemid 29220644)
2. Ranum LP, Day JW. Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2. Curr Neurol Neurosci Rep 2002; 2:465-470.
3. Mahadevan M, Tsilfidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 30 untranslated region of the gene. Science 1992; 255:1253-1255.
4. Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293:864-867. (Pubitemid 32743976)
5. Tsilfidis C, MacKenzie AE, Mettler G, et al. Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy. Nat Genet 1992; 1:192-195.
6. Taneja KL, McCurrach M, Schalling M, et al. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol 1995; 128:995-1002.
7. Timchenko LT, Miller JW, Timchenko NA, et al. Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res 1996; 24:4407-4414. (Pubitemid 26388627)
8. Tiscornia G, Mahadevan MS. Myotonic dystrophy: the role of the CUG triplet repeats in splicing of a novel DMPK exon and altered cytoplasmic DMPK mRNA isoform ratios. Mol Cell 2000; 5:959-967.
9. Miller JW, Urbinati CR, Teng-Umnuay P, et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. Embo J 2000; 19:4439-4448.
10. Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 1998; 280:737-741. (Pubitemid 28243348)
11. Amack JD, Paguio AP, Mahadevan MS. Cis and trans effects of the myotonic dystrophy (DM) mutation in a cell culture model. Hum Mol Genet 1999; 8:1975-1984. (Pubitemid 29458723)
12. Mankodi A, Logigian E, Callahan L, et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 2000; 289:1769-1773.
13. Savkur RS, Philips AV, Cooper TA, et al. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet 2004; 74:1309-1313. (Pubitemid 38669332)
14. Ranum LP, Day JW. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet 2004; 74:793-804. (Pubitemid 38568955)
15. Mankodi A, Urbinati CR, Yuan QP, et al. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet 2001; 10:2165-2170. (Pubitemid 32998828)
16. Jiang H, Mankodi A, Swanson MS, et al. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet 2004; 13:3079-3088. (Pubitemid 40045262)
17. Mankodi A, Lin X, Blaxall BC, et al. Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res 2005; 97:1152-1155.
18. Du H, Cline MS, Osborne RJ, et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol 2010; 17:187-193.
19. Wheeler TM, Lueck JD, Swanson MS, et al. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 2007; 117:3952-3957. (Pubitemid 350224104)
20. Fugier C, Klein AF, Hammer C, et al. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med 2011; 17:720-725.
21. Orengo JP, Ward AJ, Cooper TA. Alternative splicing dysregulation secondary to skeletal muscle regeneration. Ann Neurol 2011; 69:681-690.
22. Kanadia RN, Johnstone KA, Mankodi A, et al. A muscleblind knockout model for myotonic dystrophy. Science 2003; 302:1978-1980. (Pubitemid 37523508)
23. Kanadia RN, Shin J, Yuan Y, et al. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci USA 2006; 103:11748-11753. (Pubitemid 44182522)
24. Wheeler TM, Sobczak K, Lueck JD, et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009; 325:336-339.
25. Holt I, Jacquemin V, Fardaei M, et al. Muscleblind-like proteins: similarities and differences in normal and myotonic dystrophy muscle. Am J Pathol 2009; 174:216-227.
26. Querido E, Gallardo F, Beaudoin M, et al. Stochastic and reversible aggregation of mRNA with expanded CUG-triplet repeats. J Cell Sci 2011; 124 (Pt 10):1703-1714.
27. Ward AJ, Rimer M, Killian JM, et al. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet 2010; 19:3614-3622.
28. Timchenko NA, Cai ZJ, Welm AL, et al. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem 2001; 276:7820-7826.
29. Mahadevan MS, Yadava RS, Yu Q, et al. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet 2006; 38:1066-1070. (Pubitemid 44325934)
30. Orengo JP, Chambon P, Metzger D, et al. Expanded CTG repeats within the DMPK 30 UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci USA 2008; 105:2646-2651. (Pubitemid 351520567)
31. Lin X, Miller JW, Mankodi A, et al. Failure of MBNL1-dependent postnatal splicing transitions in myotonic dystrophy. Hum Mol Genet 2006; 15:2087-2097. (Pubitemid 43923398)
32. Amack JD, Mahadevan MS. The myotonic dystrophy expanded CUG repeat tract is necessary but not sufficient to disrupt C2C12 myoblast differentiation. Hum Mol Genet 2001; 10:1879-1887. (Pubitemid 32910532)
33. Margolis JM, Schoser BG, Moseley ML, et al. DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Hum Mol Genet 2006; 15:1808-1815. (Pubitemid 43821771)
34. Wheeler TM, Thornton CA. Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol 2007; 20:572-576. (Pubitemid 47462288)
35. Yadava RS, Frenzel-McCardell CD, Yu Q, et al. RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat Genet 2008; 40:61-68.
36. Ravel-Chapuis A, Belanger G, Yadava RS, et al. The RNA-binding protein Staufen1 is increased in DM1 skeletal muscle and promotes alternative premRNA splicing. J Cell Biol 2012; 196:699-712.
37. Rau F, Freyermuth F, Fugier C, et al. Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. Nat Struct Mol Biol 2011; 18:840-845.
38. Perbellini R, Greco S, Sarra-Ferraris G, et al. Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscul Disord 2011; 21:81-88.
39. Gambardella S, Rinaldi F, Lepore SM, et al. Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients. J Transl Med 2010; 8:48.
40. Paul S, Dansithong W, Jog SP, et al. Expanded CUG repeats dysregulate RNA splicing by altering the stoichiometry of the muscleblind 1 complex. J Biol Chem 2011; 286:38427-38438.
41. Laurent FX, Sureau A, Klein AF, et al. New function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeats. Nucleic Acids Res 2012; 40:3159-3171.
42. Yu Z, Teng X, Bonini NM. Triplet repeat-derived siRNAs enhance RNAmediated toxicity in a Drosophila model for myotonic dystrophy. PLoS Genet 2011; 7:e1001340.
43. Zu T, Gibbens B, Doty NS, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci USA 2011; 108:260-265.
44. Seznec H, Agbulut O, Sergeant N, et al. Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities. Hum Mol Genet 2001; 10:2717-2726. (Pubitemid 33133413)
45. Bhakta D, Shen C, Kron J, et al. Pacemaker and implantable cardioverterdefibrillator use in a US myotonic dystrophy type 1 population. J Cardiovasc Electrophysiol 2011; 22:1369-1375.
46. Laurent V, Pellieux S, Corcia P, et al. Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices. Int J Cardiol 2011; 150:54-58.
47. Hiba B, Richard N, Hebert LJ, et al. Quantitative assessment of skeletal muscle degeneration in patients with myotonic dystrophy type 1 using MRI. J Magn Reson Imaging 2012; 35:678-685.
48. Warf MB, Nakamori M, Matthys CM, et al. Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci USA 2009; 106:18551-18556.
49. Garcia-Lopez A, Llamusi B, Orzaez M, et al. In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models. Proc Natl Acad Sci USA 2011; 108:11866-11871.
50. Childs-Disney JL, Hoskins J, Rzuczek SG, et al. Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem Biol 2012; 7:856-862.
51. Wong CH, Fu Y, Ramisetty SR, et al. Selective inhibition of MBNL1-CCUG interaction by small molecules toward potential therapeutic agents for myotonic dystrophy type 2 (DM2). Nucleic Acids Res 2011; 39:8881-8890.
52. Parkesh R, Childs-Disney JL, Nakamori M, et al. Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motifligand database and chemical similarity searching. J Am Chem Soc 2012; 134:4731-4742.
53. Mulders SA, van den Broek WJ, Wheeler TM, et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci USA 2009; 106:13915-13920.
54. Lee JE, Bennett CF,Cooper TA.RNase H-mediated degradation of toxicRNAin myotonic dystrophy type 1. Proc Natl Acad Sci USA 2012; 109:4221-4226.
55. Francois V, Klein AF, Beley C, et al. Selective silencing of mutated mRNAs in DM1 by using modified hU7-snRNAs. Nat Struct Mol Biol 2011; 18:85-87.